News >

Overcoming Targeted Therapy Resistance in NSCLC

Caroline Seymour
Published: Thursday, Oct 24, 2019

Timothy F. Burns, MD, PhD

Timothy F. Burns, MD, PhD

Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding options for those with progressive disease, explained Timothy F. Burns, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication